Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: GlobeNewswire
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing. Total gross proceeds from the offering are approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the “Offering”). The Offering closed on March 31, 2026. The Company intends to use the upfront net proceeds for general corporate purposes and for research and development expenses. The private placement was led by Soleus Capital with participation from other new investors, including Vestal Point Capital and Squadron Capital Management, existing investors and certain insiders of the Company. In connection with the Offering the Company sold (i) pre-f
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Frazier Life Sciences Appoints Christian Schade as Senior AdvisorBusiness Wire
- Aprea Therapeutics (APRE) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Aprea Therapeutics (APRE) had its price target lowered by HC Wainwright from $4.00 to $1.20. They now have a "buy" rating on the stock.MarketBeat
- Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics Announces Oversubscribed $30 Million Private PlacementGlobeNewswire
APRE
Sec Filings
- 4/7/26 - Form SCHEDULE
- 4/1/26 - Form SCHEDULE
- 4/1/26 - Form 4
- APRE's page on the SEC website